¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"maximum target dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • infective dose
    °¨¿°¿ë·®, °¨¿°·®
  • integral dose
    ÀûºÐ¼±·®
  • lethal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • loading dose
    ºÎÇϿ뷮, ºÎÇÏ·®
  • low dose rate
    Àú¼±·®·ü
  • low dose rate irradiation
    Àú¼±·®·üÁ¶»ç
  • low-dose tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • maintenance dose
    À¯Áö¿ë·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°¿ë·®
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • minimum dose
    1. ÃÖ¼Ò¿ë·® 2. ÃÖ¼Ò¼±·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • dose rate meter
    ¼±·®À²°è, ¼±·®·üÃøÁ¤±â
  • dose rate variation
    ¼±·®·üº¯ÀÌ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • erythema dose
    È«¹Ý¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • fatal dose
    Ä¡»ç¿ë·®, Ä¡»ç¼±·®
  • fractional dose
    ºÐÇÒ¿ë·®, ºÐÇÒ¼±·®
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • infective dose
    °¨¿°¿ë·®, °¨¿°·®
  • integral dose
    Àû»ê¹æ»ç¼±·®
  • lethal dose
    Ä¡»ç¿ë·®, Ä¡»ç·®, Ä¡»ç¼±·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • maximum permissible concentration =MPC
    ÃÖ´ëÇã¿ë³óµµ(¡­úÉé»ÒØöô).
  • maximum permissible level
    ÃÖ´ëÇã¿ë¼öÁØ.
  • maximum permissible limit
    ÃÖ´ëÇã¿ëÇѰè(õÌÓÞúÉé»ùÚÍ£).
  • maximum phonation time
    ÃÖÀå ¹ß¼ºÁö¼Ó½Ã°£
  • maximum power output =MPO
    ÃÖ´ëÃâ·Â
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ.
  • maximum safety pressure
    ÃÖ´ë¾ÈÀü¾Ð.
  • maximum security unit
    ÃÖ´ë¾ÈÀüº´µ¿
  • maximum stationary phase (of growth)
    (Áõ½Ä)±Ø´ëÁ¤Áö±â(ñòãÖпÓÞïÎò­Ñ¢).
  • maximum surgical blood order schedule
    ÃÖ´ë¼ö¼úÇ÷¾×¿äû¿¹Á¤Ç¥
  • maximum urea clearance
    ÃÖ°í¿ä¼Ò(õÌÍÔèñáÈ)Ŭ¸®¾î·±½º.
  • maximum urethral closure pressure
    ÃÖ°í ¿äµµÆó¼â¾Ð
  • maximum urethral pressure
    ÃÖ°í¿äµµ¾Ð
  • maximum vapor pressure
    ÃÖ°íÁõ±â¾Ð(̧˭̡˻Ëâ).
  • maximum vapor pressure
    ÃÖ°íÁõ±â¾Ð(õÌÍÔñúѨäâ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
FTAG, F-TAG fast-binding target-attaching globulin
MLTI mixed lymphocyte target interaction
MTI malignant teratoma, intermediate; minimum time interval; moving target indicator
NTE neuropathy target esterase; neurotoxic esterase; not to exceed
OTC ornithine transcarbamylase; oval target cell; over-the-counter; oxytetracycline
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
MEM Maximum Entropy Method
MIP Maximum Intensity Projection
MLS Maximum Length Sequences
ML Maximum Likelihood
MLE Maximum Likelihood Estimate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • midbreast dose
    À¯¹æ Áß¾Ó Á¶»ç¼±·®
  • minimal dose
    ÃÖ¼Ò·®
  • minimum dose
    ÃÖ¼Ò·®
  • minimum hemolytic dose
    ÃÖ¼Ò ¿ëÇ÷·®
  • minimum inhibitory dose
    ÃÖ¼Ò ¾ïÁ¦·®
  • minimum reacting dose
    ÃÖ¼Ò ¹ÝÀÀ·®
  • optimal dose
    ÃÖÀû·®, ÀûÁ¤·®
  • oral dose
    ±¸°­ ¿ë·®
  • organ tolerance dose
    ±â°ü Çã¿ë·®, Àå±â Çã¿ë·®
  • permissible dose
    Çã¿ë·®
  • radiation dose
    ¼±·®
    ¹°ÁúÀ̳ª Á¶Á÷ ¶Ç´Â Àü½Å ¹× ±¹ºÎ µîÀÌ ¹ÞÀº ¹æ»ç¼±ÀÇ ¾ç. Á¶»ç ½Ã°£ ÁßÀÇ ¹æ»ç¼± ¿¡³ÊÁöÀÇ Èí¼ö·®¿¡ ÇØ´çÇÑ´Ù.
  • skin dose
    ÇǺΠ¼±·®
  • therapeutic dose
    Ä¡·á·®, Ä¡·á ¿ë·®
  • total dose
    Àü·®, ÃѼ±·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 6
L+ dose The limes tod dose of diphtheria toxin, i.e., the smallest amount of toxin that, when mixed with one unit of antitoxin and injected subcutaneously into a 250-g guinea pig, results in death of the animal within 96 hours (based on the average in a series); on theoretical grounds, one might expect that the difference between the L+ and L0 dose's would be identical to 1 MLD, but this is not so in actual practice; with various toxic filtrates, the difference may range from several to more than 100 MLD's, indicating that the toxin-antitoxin combination is not a firm chemical union that occurs in constant proportions.
(05 Mar 2000)
lethal dose <pharmacology> The amount, or dosage, of a toxin necessary to cause death.
(16 Mar 1998)
lethal dose 50 <pharmacology> The amount, or dosage, of a toxin necessary to kill 50% of the experimental subjects.
(16 Mar 1998)
Lf dose The limes flocculation dose of diphtheria toxin, i.e., the smallest amount of toxin that, when mixed with one unit of antitoxin, yields the most rapid flocculation in the Ramon test (in vitro); in general, the Lf dose is slightly less than the Lr dose.
(05 Mar 2000)
loading dose <pharmacology> A quantity higher than the average or maintenance dose, used at the initiation of therapy to rapidly establish a desired level of the drug
(18 Nov 1997)
Lo dose <pharmacology> The limes nul dose of diphtheria toxin, i.e., the largest amount of toxin that, when mixed with one unit of antitoxin and injected subcutaneously into a 250-g guinea pig, yields no recognizable reaction in the average of a series; actually, the Lod. Is usually recorded as the one that causes a barely perceptible local oedema at the site of inoculation.
(05 Mar 2000)
Lr dose The limes reacting dose of diphtheria toxin, i.e., the smallest amount of toxin that, when mixed with one unit of antitoxin and injected intracutaneously in the shaved skin of a susceptible guinea pig, yields a minimal, positive reaction and inflammation localised to the region of the injection; the Lrd. Closely approximates the Lod., as would be expected, inasmuch as a slight excess of unneutralised toxin results in a reaction.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á